Dinesh Thakur says the country needs strict criminal prosecution against suppliers of substandard drugs, a nationwide product recall system.

“Based on our understanding of the matter, there is no truth to the assertions you are making,” a Sun spokesperson said in an email to ET.

Sharma wants three manufacturing sites banned on the grounds that they allegedly supplied adulterated drugs from these facilities.

In a writ petition filed at the Supreme Court of India, Thakur has sued the health ministry , Central Drugs Standard Control Organisation .

Thakur is considering plans to set up a patient advocacy group that will aim to increase transparency and accountability among drug makers ...

There has been a fourfold jump in the number of Indians reporting secret tips about misconduct and fraudulent practices to US regulators, a...

Prime Minister-designate Narendra Modi moved home from Ahmedabad to Delhi on Thursday evening, after meeting his mother Hiraben at her Gand...

'There is a growing perception in the US that India’s drug regulator is unwilling to monitor the quality of drugs manufactured by the local...

Considering that some of the cases were very sensitive, a minimum guarantee from the govt for whistle-blower is a basic pre-requisite, Thak...

Ranbaxy Labs used "fraudulent" data to get USFDA nod to sell its generic drugs, according to whistleblower Dinesh Thakur, who also accused ...

"I have no idea what other Indian companies do.... I made sure that patients didn't suffer because of the quality of medicines made by Ranb...

Daiichi Sankyo has accused Malvinder Singh of concealing and misrepresenting crucial information regarding the US authorities investigations

Singh described the testimony of whistleblower that formed the basis of investigations as 'sensational', and said he rejected these charges.

A series of revelations by Dinesh Thakur indicates that how troubles at Ranbaxy Laboratories were because of the fraudulent practices.

Former chief justice of Delhi High Court Rajinder Sachar has demanded that Indian authorities take steps to stop their use in the country.

Dinesh Thakur, pocketed Rs 244 crore for blowing the whistle on the dubious manufacturing practices of the country's largest drug maker Ran...

Thakur, a former director of research information at Ranbaxy, has claimed that senior company executives ordered destruction of evidence.